A biotech company focused on developing therapeutics for fibrotic diseases was looking at acquisitions or in-licensing as a way to grow its development pipeline with additional assets. Alacrita was engaged to conduct scouting activities and identify first-in-class assets for fibrosis, between candidate selection and Phase 2 clinical development.


Alacrita’s search strategy included both desk analytics and primary research to identify a long list of potential opportunities. Where specific assets were deemed to be of high interest to our client, a more in-depth scientific analysis was conducted by our in-house fibrosis expert with over 30 years of experience in drug development in this space. As a result of our work, we identified and presented a series of high quality new business development opportunities for our client to consider.


Alacrita's Asset Scouting & In-Licensing Services

Alacrita supports both large pharma and biotech companies with their search and evaluation activities. Our scouting support is often structured to integrate with the client’s internal efforts, resulting in a constant flow of new opportunities.

Click here to learn more